Minghui Bi1, Zhuo Huang1, Peng Li2, Cheng Cheng3, Yuli Huang4, Weibing Chen5. 1. Xiamen Hospital of Traditional Chinese Medicine Xiamen 361009, China. 2. The Fifth Affiliated Hospital of Sun Yat-sen University Zhuhai 519000, China. 3. Southern Medical University Guangzhou 510515, China. 4. The Affiliated Hospital at Shunde, Southern Medical University Foshan 528300, China. 5. Xiamen Cardiovascular Hospital Xiamen 361000, China.
Abstract
OBJECTIVE: Cystatin C is a well established marker of kidney function. There is evidence that cystatin C concentrations are also associated with myocardial infarction. The purpose of the present study is to clarify the link between cystatin C with myocardial infarction using a meta-analysis approach. METHODS: We searched articles indexed in the Pubmed and Sciencedirect published as of August 2015 that met our predefined criteria. A meta-analysis was used to pool estimates of the multivariate adjusted relative risk (RR) with 95% confidence interval (CI), of the association between cystatin C and subsequent risk of myocardial infarction. RESULTS: Four eligible articles with 10491 subjects from 5 cohort studies were considered in the analysis. Overall, the random-effects meta-analysis results indicated that the highest cystatin C category versus lowest was associated with greater risk of myocardial infarction (RR, 1.78; 95% CI, 1.27 to 2.49; P=0.001). No evidence of publication bias was observed. CONCLUSIONS: This meta-analysis showed that cystatin C is strongly and independently associated with subsequent risk of myocardial infarction. Further investigation is warranted to clarify whether measurement of cystatin C can usefully reduce the myocardial infarction beyond established predictors already in clinical use.
OBJECTIVE:Cystatin C is a well established marker of kidney function. There is evidence that cystatin C concentrations are also associated with myocardial infarction. The purpose of the present study is to clarify the link between cystatin C with myocardial infarction using a meta-analysis approach. METHODS: We searched articles indexed in the Pubmed and Sciencedirect published as of August 2015 that met our predefined criteria. A meta-analysis was used to pool estimates of the multivariate adjusted relative risk (RR) with 95% confidence interval (CI), of the association between cystatin C and subsequent risk of myocardial infarction. RESULTS: Four eligible articles with 10491 subjects from 5 cohort studies were considered in the analysis. Overall, the random-effects meta-analysis results indicated that the highest cystatin C category versus lowest was associated with greater risk of myocardial infarction (RR, 1.78; 95% CI, 1.27 to 2.49; P=0.001). No evidence of publication bias was observed. CONCLUSIONS: This meta-analysis showed that cystatin C is strongly and independently associated with subsequent risk of myocardial infarction. Further investigation is warranted to clarify whether measurement of cystatin C can usefully reduce the myocardial infarction beyond established predictors already in clinical use.
Authors: Linda F Fried; Michael G Shlipak; Casey Crump; Anthony J Bleyer; John S Gottdiener; Richard A Kronmal; Lewis H Kuller; Anne B Newman Journal: J Am Coll Cardiol Date: 2003-04-16 Impact factor: 24.094
Authors: Marta Negrusz-Kawecka; Rafał Poręba; Anna Hulok; Krzysztof Sciborski; Jakub Marczak; Tomasz Bańkowski Journal: Adv Clin Exp Med Date: 2014 Jul-Aug Impact factor: 1.727
Authors: Johannes Arpegård; Alexander Viktorin; Zheng Chang; Ulf de Faire; Patrik K E Magnusson; Per Svensson Journal: J Am Heart Assoc Date: 2015-01-14 Impact factor: 5.501